摘要
新型冠状病毒肺炎患者不仅具有典型的呼吸道症状,同时也表现出一定程度的心脏损伤。合并心血管疾病的新型冠状病毒肺炎患者病情容易恶化,病死率高。冠心病作为中老年人最常见的心血管疾病广泛存在于重症新型冠状病毒肺炎患者中,对病程转归造成严重的影响。本文将探讨重症新型冠状病毒肺炎对冠心病患者药物治疗的影响,以优化治疗策略,改善患者的预后。
Patients with corona virus disease 2019(COVID-19)presented typical respiratory symptoms,as well as a certain degree of cardiac injury.COVID-19 patients with cardiovascular diseases are prone to deterioration and high mortality.Coronary heart disease,as the most common cardiovascular disease in the middle-aged and the elderly,widely exists in severe COVID-19 patients,which has a serious impact on the course of disease.This article will discuss the influence of severe COVID-19 on the drug treatment of coronary heart disease,to optimize the treatment strategy and improve the prognosis of patients.
作者
叶添宝
沈成兴
YE Tianbao;SHEN Chengxing(Department of Cardiology,Shanghai Sixth People's Hospital,Shanghai Jiaotong University,Shanghai 200233,China)
出处
《中国动脉硬化杂志》
CAS
2020年第5期382-385,共4页
Chinese Journal of Arteriosclerosis
基金
国家自然科学基金项目(81871105)。
关键词
新型冠状病毒肺炎
冠心病
药物治疗
corona virus disease 2019
coronary heart disease
drug therapy